Glenmark Pharmaceuticals
Glenmark Pharmaceuticals Ltd., commonly referred to as Glenmark, is a prominent global player in the pharmaceutical industry, headquartered in India. Founded in 1977, the company has established a strong presence in various operational regions, including North America, Europe, and emerging markets. Glenmark focuses on the development and manufacturing of innovative generics, specialty pharmaceuticals, and over-the-counter products. With a diverse portfolio that includes formulations in therapeutic areas such as dermatology, oncology, and respiratory, Glenmark is recognised for its commitment to research and development. The company has achieved significant milestones, including numerous product approvals and a robust pipeline of new therapies. Glenmark's dedication to quality and innovation has positioned it as a trusted name in the pharmaceutical sector, making notable strides in both domestic and international markets.
DitchCarbon Score
How does Glenmark Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Glenmark Pharmaceuticals's score of 63 is higher than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Glenmark Pharmaceuticals's reported carbon emissions
In 2024, Glenmark Pharmaceuticals reported total greenhouse gas emissions of approximately 15240000 kg CO2e for Scope 1, 69622000 kg CO2e for Scope 2, and 170970000 kg CO2e for Scope 3. This reflects a commitment to transparency in emissions reporting, with data disclosed across all three scopes. The company has set ambitious targets to achieve carbon neutrality by 2030 for its Scope 1 and Scope 2 emissions, as part of its focused decarbonisation initiatives. Additionally, Glenmark aims to reduce its absolute Scope 1 and 2 GHG emissions by 35% by FY2035 from a FY2021 baseline. For Scope 3 emissions, which include categories such as purchased goods and services, fuel and energy-related activities, and downstream transportation, the company targets a reduction of 28% per ton of pharmaceutical products within the same timeframe. Glenmark's emissions data is independently reported and does not cascade from any parent organisation, ensuring that their commitments and targets are specific to their operations. The company is committed to aligning its strategies with industry standards to mitigate climate change impacts effectively.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 11,713,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 74,231,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 3,277,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Glenmark Pharmaceuticals is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
